Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

semaglutide

- PMLiVE

US judge cuts billions from Takeda/Lilly Actos payment

Court rules that companies must now pay damages of $36.8m rather than $9bn

- PMLiVE

US investigates Novo Nordisk manufacturing issues

Issues subpoena related to insulin plant in Kalundborg, Denmark

- PMLiVE

Regeneron top science employer, says survey

Ranked highest for third year in a row

- PMLiVE

Novo Nordisk’s Xultophy diabetes combo approved in Europe

Once-daily injection combines the firm's Tresiba and Victoza

- PMLiVE

FDA panel backs Novo Nordisk’s liraglutide for obesity

Committee says diabetes drug could be used to reduce weight

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Lilly says peglispro tops Lantus in diabetes trials

New insulin demonstrates superiority to Sanofi’s product in cutting blood sugar levels

- PMLiVE

Novo Nordisk gives up on inflammation R&D

Follows disappointing trial results for arthritis drug

- PMLiVE

Novo Nordisk debuts diabetes combo in Mexico

Requires fewer daily injections than current insulin treatment

- PMLiVE

Team Novo Nordisk to compete in The Tour of Britain

World’s first all-diabetes pro-cycling team will cycle over 1,300km in eight days

- PMLiVE

NICE wants more data on Boehringer’s Jardiance

Pharma company needs to demonstrate cost-effectiveness of its diabetes drug

- PMLiVE

Novo launches diabetes campaign in Copenhagen

Follows introduction of ‘Cities Changing Diabetes’ programme in Mexico

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links